Pediatric Immunization

A new study points to the Pfizer shot's initially limited protection against the COVID-19 Omicron variant in those aged 5-11 years and also the the value of vaccine boosters.

The FDA amended Pfizer and Moderna EUAs for updated COVID-19 vaccines to include children as young as age 6 months as holidays and winter weather approach.

Pfizer and BioNTech submitted an application to the FDA for emergency use authorization of their omicron BA.4/BA.5-adapted bivalent COVID-19 vaccines in children aged 6 months to 4 years.

Your daily dose of clinical news you may have missed.

One in 7 parents have not discussed vaccines with their child's primary clinician during the 2-year pandemic period, according to a CS Mott Children's Hospital poll.

Overall flu activity is at a 10-year high, according to the CDC's most recent influenza surveillance report, while US hospitals are already overwhelmed.

The overall US COVID-19 vaccination picture has both bright spots and dark areas. Get a quick look at details from the most recent KFF Vaccine Monitor survey.

The FDA amended EUAs for omicron-adapted vaccines from both Pfizer and Moderna, authorizing the shots for children and adolescents.

Refractory adult misbeliefs about vaccine safety have increased reluctance to vaccinate US children aged 5-11 years, according to an Annenberg Public Policy center survey.

Pediatric COVID-19 vaccination can be tricky as vaccine antigen levels vary by age groups. These 3 patient scenarios may help clarify.